


VESICARE™ has a favourable tolerability Profile¹



The most common reported adverse reaction with Vesicare™ 5mg once daily is "dry mouth" which occurs in 11% of the patients.²

89% of the patients do not report "dry mouth" by Vesicare™ 5mg

🍷 This balance of tolerability and efficacy with Vesicare™ was associated with excellent persistence with therapy¹

For full prescribing information please refer to SmPC of product which is attached to this email.
Adverse events should be reported. Report adverse events to the local regulatory authority:
Behestan Tolid: safety@behestan-mfg.com, Astellas Office: pv@apint-ne.com

References:

1. Haab F et al. Eur Urol. 2005 Mar;47(3):376-84. Version (3)
2. Vesicare-SmPC-IR-en-August 2019



BEHESTAN TOLID(P.J.S)

Head office:

No.1, 1st St.,Kurdistan Highway, Tehran,Iran
Postal Code :1991933771
Tel: +98 (21) 88647354 Fax: +98 (21) 88647349

Manufacturing Site:

Kargar Blvd,Azadegan 2 St,Kaveh Industrial City,
Saveh, Iran Tel: +98 (86) 42342260
Fax : +98 (86) 42342260 Ext 542

